GLP-3 RT
-13%
4X Tested - ISO 17025
99.65% View COA
Metabolic Peptide

GLP-3 RT

Certificate of Analysis

GLP-3 RT is a 39-amino acid triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, studied in clinical trials for its effects on weight reduction and metabolic regulation.

BUNDLE & SAVE
2-Day Shipping

Free Shipping
over $200

Free shipment
protection

Secure Checkout
256-bit SSL

Description

What is GLP-3 RT?

GLP-3 RT (LY3437943) is a synthetic 39-amino acid peptide that acts as a triple agonist of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

By targeting three metabolic receptors simultaneously, GLP-3 RT represents the next evolution beyond dual-action peptides like GLP-2 TZ. The glucagon receptor component adds the potential for increased energy expenditure and fat breakdown, while GIP and GLP-1 activation address insulin secretion and appetite regulation.

In Phase II clinical trials, GLP-3 RT demonstrated substantial weight reduction, with some participants achieving over 24% body weight loss over 48 weeks. Phase III trials are currently underway.

GLP-3 RT is not approved by the FDA for any medical use. Research-grade product is sold strictly for laboratory and research purposes only.

Research Applications

Areas of Investigation
Triple Action

Triple Receptor Agonism

The first triple-acting peptide targeting GLP-1, GIP, and glucagon receptors simultaneously for synergistic metabolic effects.
Weight Loss

Body Weight Reduction

Demonstrated substantial weight loss in Phase II trials, with some participants achieving over 24% body weight reduction.
Fat Burning

Energy Expenditure

Glucagon receptor activation is studied for its potential to increase thermogenesis and fat oxidation.
Blood Sugar

Glucose Regulation

Investigated for glucose-lowering effects through combined GLP-1 and GIP receptor activation.
Liver Health

Liver Health

Under evaluation for effects on metabolic dysfunction-associated steatotic liver disease in clinical trials.

Compound Profile

Technical specifications
What is GLP-3 RT?

Molecular Profile

Sequence
YXQGTFTSDYSI xLLDKK* AQXAFIEYLLEG GPSSGAPPPS NH₂
Molecular Formula
C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight
4,731.33 g/mol
Appearance
White lyophilized powder

Form

Lyophilized (freeze-dried)
Handling & Shelf Life Guidelines

Storage & Stability

Storage (Pre-Reconstitution)

Store below -20°C, desiccated, away from light and moisture.
Storage (Post-Reconstitution)
Refrigerate at 2–8°C. For longer storage, aliquot and store below -18°C. Avoid freeze-thaw cycles.
Shelf Life
24 months from date of manufacture when stored as directed
Sensitivity Notes
Sensitive to heat, light, and moisture. Keep sealed until use.
Compliance & Clinical Overview

Regulatory & Research Status

FDA Status
Not approved for human use. Investigational compound in active clinical trials.
WADA Classification
Not currently listed (subject to change as regulatory status evolves).
Clinical Trial Status
Growing body of preclinical and clinical research on triple-receptor agonism, weight management, and metabolic outcomes.
Published Studies
Growing body of preclinical and clinical research on triple-receptor agonism, weight management, and metabolic outcomes.
Research Disclaimer
For laboratory and research purposes only. Not intended for human consumption.

COA's (Certificate of Analysis)

Third Party Tested by Freedom Diagnostics
99.65%
Purity
Variant
GLP-3 RT
Lot #
GL-2609-016
Labelled
10mg
Actual
10.31mg
Tested
9/21/2026
View COA
(opens in a new tab)
99.90%
Purity
Variant
GLP-3 RT
Lot #
GL-2609-017
Labelled
15mg
Actual
15.98mg
Tested
9/21/2026
View COA
(opens in a new tab)
98.85%
Purity
Variant
GLP3-RT
Lot #
GL-3RT-20mg
Labelled
20mg
Actual
20.4mg
Tested
10/08/2026
View COA
(opens in a new tab)
99.45%
Purity
Variant
GLP-3 RT
Lot #
GL-2609-020
Labelled
50mg
Actual
52.96mg
Tested
9/21/2026
View COA
(opens in a new tab)
99.73%
Purity
Variant
GLP-3 RT
Lot #
GL-2609-019
Labelled
30mg
Actual
31.55mg
Tested
9/21/2026
View COA
(opens in a new tab)
99.94%
Purity
Variant
GLP-3 RT
Lot #
GLP3RT20-GL01
Labelled
20mg
Actual
20.6mg
Tested
7/23/2026
View COA
(opens in a new tab)
99.00%
Purity
Variant
GLP-3RT
Lot #
GLP3RT10-GL01
Labelled
10mg
Actual
10.32mg
Tested
6/24/2026
View COA
(opens in a new tab)
99.80%
Purity
Variant
GLP3-RT
Lot #
GLP3RT50-GL01
Labelled
50mg
Actual
52.48mg
Tested
6/26/2026
View COA
(opens in a new tab)
99.43%
Purity
Variant
GLP-3RT
Lot #
GLP3RT15-GL01
Labelled
15mg
Actual
15.39mg
Tested
6/24/2026
View COA
(opens in a new tab)
99.77%
Purity
Variant
GLP3-RT
Lot #
GLP3RT30-GL01
Labelled
30mg
Actual
31.12mg
Tested
6/24/2026
View COA
(opens in a new tab)
99.89%
Purity
Variant
GLP3-RT
Lot #
GLZ-GLP-3-RT-20MG-A
Labelled
20mg
Actual
23.89mg
Tested
5/11/2026
View COA
(opens in a new tab)
99.87%
Purity
Variant
GLP3-RT
Lot #
GLZ-GLP-3-RT-10MG-A
Labelled
10mg
Actual
11.41mg
Tested
3/29/2026
View COA
(opens in a new tab)

Frequently Asked Questions

Common questions about GLP-3 RT research